GenMark Diagnostics (GNMK) 10-Q 2 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Oct. 27, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	GenMark Diagnostics, Inc.
Entity Central Index Key	1,487,371
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		54,795,061

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 27,161,000	$ 15,959,000
Marketable securities	59,756,000	25,607,000
Accounts receivable, net of allowances of $2,792 and $2,740, respectively	7,800,000	9,048,000
Inventories	7,109,000	6,633,000
Prepaid expenses and other current assets	1,971,000	1,202,000
Total current assets	103,797,000	58,449,000
Property and equipment, net	21,586,000	18,268,000
Intangible assets, net	2,772,000	2,670,000
Cash, Cash Equivalents, and Short-term Investments	86,917,000
Restricted cash	758,000	758,000
Other long-term assets	194,000	179,000
Total assets	129,107,000	80,324,000
Current liabilities
Accounts payable	7,242,000	8,703,000
Accrued compensation	5,227,000	5,650,000
Loan payable	19,548,000	7,935,000
Other current liabilities	2,923,000	4,133,000
Liabilities, Current	34,940,000	26,421,000
Long-term liabilities
Deferred rent	3,225,000	3,652,000
Long-term Debt, Excluding Current Maturities	9,918,000	11,880,000
Other non-current liabilities	387,000	220,000
Total liabilities	48,470,000	42,173,000
Stockholders’ equity
Preferred stock, $0.0001 par value; 5,000 authorized, none issued	0	0
Common stock, $0.0001 par value; 100,000 authorized; 54,792 and 46,554 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively	5,000	4,000
Additional paid-in capital	483,242,000	393,322,000
Accumulated deficit	(402,584,000)	(355,270,000)
Accumulated other comprehensive income	(26,000)	95,000
Total stockholders’ equity	80,637,000	38,151,000
Total liabilities and stockholders’ equity	$ 129,107,000	$ 80,324,000

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Allowance for Doubtful Accounts Receivable, Current	$ 2,792	$ 2,740
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, authorized	100,000,000	100,000,000
Common stock, issued	54,665,000	46,554,000
Common stock, outstanding	54,665,000	46,554,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue
Product revenue	$ 11,552,000	$ 10,727,000	$ 36,313,000	$ 34,111,000
License and other revenue	51,000	86,000	184,000	278,000
Total revenue	11,603,000	10,813,000	36,497,000	34,389,000
Cost of revenue	7,400,000	4,362,000	21,227,000	13,457,000
Gross profit	4,203,000	6,451,000	15,270,000	20,932,000
Operating expenses
Sales and marketing	5,121,000	3,223,000	14,974,000	10,232,000
General and administrative	3,565,000	3,227,000	11,553,000	10,522,000
Research and development	10,248,000	11,628,000	34,297,000	37,100,000
Total operating expenses	18,934,000	18,078,000	60,824,000	57,854,000
Loss from operations	(14,731,000)	(11,627,000)	(45,554,000)	(36,922,000)
Other income (expense)
Interest income	247,000	43,000	353,000	98,000
Interest expense	1,009,000	476,000	2,270,000	1,061,000
Other income	76,000	16,000	227,000	7,000
Total other income (expense)	(686,000)	(417,000)	(1,690,000)	(956,000)
Loss before provision for income taxes	(15,417,000)	(12,044,000)	(47,244,000)	(37,878,000)
Income tax expense (benefit)	(9,000)	14,000	68,000	45,000
Net loss	$ (15,408,000)	$ (12,058,000)	$ (47,312,000)	$ (37,923,000)
Net loss per share, basic and diluted	$ (0.28)	$ (0.27)	$ (0.95)	$ (0.88)
Weighted average number of shares outstanding, basic and diluted	54,726,000	44,377,000	49,908,000	43,308,000
Other comprehensive loss
Net loss	$ 15,408,000	$ 12,058,000	$ 47,312,000	$ 37,923,000
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax	51,000	(4,000)	145,000	9,000
Net unrealized gains (losses) on marketable securities, net of tax	(9,000)	20,000	(24,000)	(2,000)
Comprehensive loss	$ (15,366,000)	$ (12,042,000)	$ (47,191,000)	$ (37,916,000)

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Operating activities
Net loss	$ 47,312	$ 37,923
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,811	2,739
Amortization of premiums on investments	4	61
Amortization of deferred debt issuance costs	891	277
Gain on sale of investment in preferred stock	0	(9)
Stock-based compensation	8,386	6,788
Provision for bad debt	51	13
Non-cash inventory adjustments	911	120
Other non-cash adjustments	(190)	20
Changes in operating assets and liabilities:
Accounts receivable	(1,272)	(1,719)
Inventories	(4,813)	(1,048)
Prepaid expenses and other assets	(767)	(596)
Other long-term assets	(16)	0
Accounts payable	(1,468)	916
Accrued compensation	(452)	1,731
Other liabilities	(913)	33
Net cash used in operating activities	(40,605)	(25,159)
Investing activities
Payments for intellectual property licenses	(500)	(800)
Purchases of property and equipment	(3,816)	(5,105)
Purchases of marketable securities	(56,525)	(32,895)
Proceeds from sales of marketable securities	13,896	9
Maturities of marketable securities	8,500	8,050
Net cash used in investing activities	(38,445)	(30,741)
Financing activities
Proceeds from issuance of common stock	86,835	30,448
Costs incurred in conjunction with stock issuance	(5,469)	(1,091)
Principal repayment of borrowings	(6,123)	(28)
Proceeds from borrowings	15,000	10,000
Costs associated with debt issuance	(187)	(30)
Proceeds from stock option exercises	(213)	(507)
Net cash provided by financing activities	90,269	39,806
Effect of exchange rate changes on cash	(17)	2
Net increase (decrease) in cash and cash equivalents	11,202	(16,092)
Cash and cash equivalents at beginning of period	15,959	35,385
Cash and cash equivalents at end of period	27,161	19,293
Non-cash investing and financing activities
Transfer of instruments from (to) property and equipment to (from) inventory	(3,438)	234
Property and equipment costs included in accounts payable	330	1,040
Intellectual property acquisitions included in other current liabilities	0	700
Supplemental cash flow disclosures
Cash paid for income taxes, net	58	38
Cash received for interest	367	58
Cash paid for interest	$ 1,143	$ 761

Organization and Basis of Prese

Organization and Basis of Presentation	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation GenMark Diagnostics, Inc., the Company or GenMark, was formed by Osmetech plc as a Delaware corporation in February 2010, and had no operations prior to its initial public offering, which was completed in June 2010. The Company is a leading provider of multiplex molecular solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP, and applicable regulations of the U.S. Securities and Exchange Commission, or the SEC, and should be read in conjunction with the audited financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2016 filed with the SEC on February 28, 2017. These unaudited condensed consolidated financial statements reflect all adjustments that are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. These adjustments are of a normal, recurring nature. Interim period operating results may not be indicative of the operating results for the full year or any future period. The Company has experienced net losses and negative cash flows from operating activities since its inception and had an accumulated deficit of $402,584,000 as of September 30, 2017 . The Company's ability to transition to profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure through expanding its product offerings and consequently increasing its product revenues. As of September 30, 2017 , the Company had available cash, cash equivalents, and marketable securities of $86,917,000 and working capital of $68,857,000 available to fund future operations. The Company has prepared cash flow forecasts which indicate, based on the Company's current cash resources available and working capital, that the Company will have sufficient resources to fund its operations for at least one year after the date the financial statements are issued. Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of these unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes thereto. The Company’s significant estimates included in the preparation of the financial statements are related to accounts receivable, inventories, property and equipment, intangible assets, employee-related compensation accruals, warranty liabilities, tax valuation accounts and stock-based compensation. Actual results could differ from those estimates. Segment Information The Company currently operates in one reportable business segment, which encompasses the development, manufacturing, sales and support of instruments and molecular tests based on its proprietary eSensor® detection technology. Substantially all of the Company’s operations and assets are in the United States of America. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that the Company adopts as of the specified effective date. In November 2016, the FASB issued Accounting Standards Update, or ASU, 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash , which requires amounts generally described as restricted cash and restricted cash equivalents to be included in the cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-08 is effective for fiscal years beginning after December 15, 2017 (including interim periods within those periods) using a retrospective transition method for each period presented. Early adoption is permitted. The Company will adopt ASU 2016-18 in the first quarter of 2018 and anticipates the impact of adoption will result in a beginning and ending cash balance increase of approximately $758,000 . The Company does not anticipate a material impact in the cash flow resulting from fluctuations in the restricted cash balance. In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting . This guidance simplifies how several aspects of share-based payments are accounted for and presented in the financial statements and is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company's adoption of this guidance in the first quarter of 2017 resulted in excess tax benefits for which a benefit could not be previously recognized of approximately $1,979,000 . Upon adoption, the balance of the unrecognized excess tax benefits was reversed with the impact recorded to retained earnings, including a corresponding change to the valuation allowance. Due to the full valuation allowance on the Company's U.S. deferred tax assets, there was no impact to the unaudited condensed consolidated financial statements as a result of adoption. The Company continues to record stock-based compensation expense net of estimated forfeitures. In February 2016, the FASB issued ASU 2016-02, Leases . This ASU outlines a comprehensive lease accounting model and supersedes the current lease guidance. The new guidance requires lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms of greater than 12 months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. The new guidance must be adopted using the modified retrospective approach and will be effective for the Company starting in the first quarter of 2019, with early adoption permitted. The Company believes that adoption will modify its analysis and disclosures of lease agreements as operating agreements are a significant portion of the Company's total lease commitments. The Company is in the process of determining the effects adoption of this guidance will have on its consolidated financial statements, as well as whether to adopt this guidance early. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, an updated standard on revenue recognition. ASU 2014-09 provides enhancements to the quality and consistency of how revenue is reported by companies while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards or U.S. GAAP. The main purpose of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which a company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures of revenue, provide guidance for transactions that were not previously addressed comprehensively, and improves guidance for multiple-element arrangements. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date , which deferred the effective date of the new revenue standard from periods beginning after December 15, 2016 to December l5, 2017, with early adoption permitted but not earlier than the original effective date. Accordingly, the updated standard is effective for the Company in the first quarter of 2018. The Company performed a preliminary assessment of the impact of ASU 2014-09 on its consolidated financial statements, and considered all items outlined in the standard. In assessing the impact, the Company has outlined all revenue generating activities, mapped those activities to deliverables and traced those deliverables to the standard. The Company is now assessing what impact the change in standard will have on those deliverables. The Company will continue to evaluate the future impact and method of adoption of ASU 2014-09 and related amendments on its consolidated financial statements and related disclosures during the remainder of 2017. The Company believes the adoption of this guidance will modify the manner in which the Company analyzes its revenue generating contracts. The Company will adopt the new standard beginning January 2018. Cash, Cash Equivalents and Marketable Securities Cash and cash equivalents consist of cash on deposit with banks, money market instruments and certificates of deposit with original maturities of three months or less at the date of purchase. Marketable securities consist of certificates of deposits that mature in greater than three months. Marketable securities are accounted for as "available-for-sale" with the carrying amounts reported in the balance sheets stated at cost, which approximates their fair market value, with unrealized gains and losses, if any, reported as a separate component of stockholders' equity and included in comprehensive loss. Restricted Cash Restricted cash represents amounts designated for uses other than current operations and included $758,000 as of September 30, 2017 , held as security for the Company’s letter of credit with Banc of California. Receivables Accounts receivable consist of amounts due to the Company for sales to customers and are recorded net of an allowance for doubtful accounts. The allowance for doubtful accounts is determined based on an assessment of the collectability of specific customer accounts, the aging of accounts receivable, and a reserve for unknown items based upon the Company’s historical experience. Product Warranties The Company generally offers a one -year warranty for its instruments sold to customers and typically up to a 60 day warranty for consumables. Factors that affect the Company’s warranty reserves include the number of units sold, historical and anticipated rates of warranty repairs, and the cost per repair. The Company periodically assesses the adequacy of its warranty reserve and adjusts the amount as appropriate. Intangible Assets Intangible assets comprise licenses or sublicenses to technology covered by patents owned by third parties, and are amortized on a straight-line basis over the expected useful lives of these assets, which is generally 10 years . Amortization of licenses typically begins upon the Company obtaining access to the licensed technology and is recorded in cost of revenues for licenses supporting commercialized products. The amortization of licenses to technology supporting products in development is recorded in research and development expenses. Impairment of Long-Lived Assets The Company assesses the recoverability of long-lived assets, including intangible assets, by periodically evaluating the carrying value whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If impairment is indicated, the Company writes down the carrying value of the asset to its estimated fair value. This fair value is primarily determined based on estimated discounted future cash flows. Inventories Inventories are stated at the lower of cost (first-in, first-out) or net realizable value and include direct labor, materials, and manufacturing overhead. The Company periodically reviews inventory for evidence of slow-moving or obsolete parts, and writes inventory down to net realizable value, as needed. This write-down is based on management’s review of inventories on hand, compared to estimated future usage and sales, shelf-life assumptions, and assumptions about the likelihood of obsolescence. If actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Inventory impairment charges establish a new cost basis for inventory and charges are not reversed subsequently to income, even if circumstances later suggest that increased carrying amounts are recoverable. Property and Equipment, net Property, equipment and leasehold improvements are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which are identified below. Repair and maintenance costs are expensed as incurred. Machinery and laboratory equipment 3 - 5 years Instruments 4 - 5 years Office equipment 3 - 7 years Leasehold improvements over the shorter of the remaining life of the lease or the useful economic life of the asset Income Taxes Current income tax expense is the amount of income taxes expected to be payable for the current year. A deferred income tax liability or asset is established for the expected future tax consequences resulting from the differences in financial reporting and tax bases of assets and liabilities. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. A full valuation allowance has been recorded against the Company’s net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the future. The Company provides for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement standards prescribed by the authoritative guidance on income taxes. Amounts for uncertain tax positions are adjusted in periods when new information becomes available or when positions are effectively settled. The Company recognizes accrued interest related to uncertain tax positions as a component of income tax expense. A tax position that is more likely than not to be realized is measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement with the taxing authority that has full knowledge of all relevant information. Measurement of a tax position that meets the more-likely-than-not threshold considers the amounts and probabilities of the outcomes that could be realized upon settlement using the facts, circumstances and information available at the reporting date.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2017
Compensation Related Costs [Abstract]
Stock-Based Compensation	Stock-Based Compensation The Company recognizes stock-based compensation expense related to stock options, restricted stock awards, restricted stock units, and market-based stock units granted to employees and directors in exchange for services under the Company's 2010 Equity Incentive Plan, or the 2010 Plan, and employee stock purchases under the Company's 2013 Employee Stock Purchase Plan, or the ESPP. Employee participation in the 2010 Plan is at the discretion of the Compensation Committee of the Board of Directors of the Company. Each equity award grant under the 2010 Plan reduces the number of shares available for grant thereunder. Stock-based compensation expense is based on the fair value of the applicable award utilizing various assumptions regarding the underlying attributes of the award. Stock-based compensation expense is recorded in cost of sales, sales and marketing, research and development, and/or general and administrative expenses based on the employee's respective function. During the nine months ended September 30, 2017 and 2016 , aggregate stock-based compensation expense was $8,386,000 and $6,788,000 , respectively. The estimated fair value, net of forfeitures expected to occur during the vesting period, is amortized as compensation expense that approximates straight-line expense to reflect vesting as it occurs. The stock option expense is derived from the Black-Scholes Option Pricing Model that uses several judgment-based variables to calculate the expense. The market-based stock unit expense is derived from the Monte Carlo Simulation Valuation. The inputs utilized in the valuation of the stock-based awards include the following factors: • Expected Term. Expected term represents the period that the stock-based awards are expected to be outstanding and is determined by using the simplified method. • Expected Volatility . Expected volatility represents the estimated volatility in the Company’s stock price over the expected term of the option or market-based award and is determined by review of the Company’s and similar companies’ historical experience. • Expected Dividend . The valuation methods require a single expected dividend yield as an input. The Company assumed no dividends as it has never paid dividends and has no current plans to do so. • Risk-Free Interest Rate. The risk-free interest rate used in the Black-Scholes Option Pricing Model is based on published U.S. Treasury rates in effect at the time of grant for periods corresponding with the expected term of the option or market-based award. All stock options granted under the 2010 Plan are exercisable at a per share price equal to the closing quoted market price of a share of the Company’s common stock on the NASDAQ Global Market on the grant date and generally vest over a period of between one and four years . Stock options are generally exercisable for a period of up to 10 years after grant and are typically forfeited if employment is terminated before the options vest. The following table summarizes stock option activity during the nine months ended September 30, 2017 : Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2016 2,569,550 $ 9.53 Granted — $ — Exercised (28,966 ) $ 7.36 Cancelled (14,427 ) $ 10.04 Outstanding at September 30, 2017 2,526,157 $ 9.56 Vested and expected to vest at September 30, 2017 2,500,450 $ 9.52 Exercisable at September 30, 2017 2,167,970 $ 9.18 Options that were exercisable as of September 30, 2017 had a remaining weighted average contractual term of 5.11 years, and an aggregate intrinsic value of $6,478,000 . As of September 30, 2017 , there were 2,526,157 stock options outstanding, which had a remaining weighted average contractual term of 5.42 years and an aggregate intrinsic value of $6,783,000 . No stock options were granted during the nine months ended September 30, 2017 . Restricted stock awards or units may be granted in connection with the hiring or retention of personnel and are subject to certain conditions. In March 2013, the Company transitioned to granting restricted stock units under the 2010 Plan in lieu of granting restricted stock awards. The compensation expense related to the restricted stock awards or units is calculated as the fair market value of the Company's stock on the grant date and is adjusted for estimated forfeitures. The Company’s restricted stock award and restricted stock unit activity for the nine months ended September 30, 2017 was as follows: Restricted Stock Awards Restricted Stock Units Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Unvested at December 31, 2016 156 $ 11.19 1,766,123 $ 7.18 Granted — $ — 1,164,250 $ 10.90 Vested (156 ) $ 11.19 (614,457 ) $ 6.80 Cancelled — $ — (165,501 ) $ 8.99 Unvested at September 30, 2017 — $ — 2,150,415 $ 9.16 As of September 30, 2017 , all compensation expense related to restricted stock awards has been recognized. The total fair value of restricted stock awards that vested during the nine months ended September 30, 2017 and 2016 was $2,000 and $152,000 , respectively. As of September 30, 2017 , there was $13,142,000 of unrecognized compensation cost related to unvested restricted stock units, which is expected to be recognized over a weighted average period of 2.76 years. The total fair value of restricted stock units that vested during the nine months ended September 30, 2017 and 2016 was $ 4,181,000 and $4,526,000 , respectively. The Company issued market-based stock units in February 2017 and February 2016, which may in each case result in the recipient receiving shares of stock equal to 200% of the target number of units granted. The vesting and issuance of Company stock pursuant to these awards depends on the Company's stock performance as compared to the NASDAQ Composite Index over a three-year period following the grant, subject to continued service with the Company. As of September 30, 2017 , there was $1,502,000 of unrecognized stock-based compensation expense related to these awards, which is expected to be recognized over a weighted average period of 1.59 years. The Company’s market-based stock unit activity for the nine months ended September 30, 2017 was as follows: Market-Based Stock Units Number of Shares Weighted Average Grant Date Fair Value Unvested at December 31, 2016 150,871 $ 11.10 Units granted 166,434 $ 13.82 Vested — $ — Cancelled (12,762 ) $ 11.90 Unvested at September 30, 2017 304,543 $ 12.55 The fair value of these market-based stock units was estimated on the grant date using the Monte Carlo Simulation Valuation Model, which estimates the potential outcome of achieving the market condition based on simulated future stock prices, with the following assumptions for the nine months ended September 30, 2017 : Nine Months Ended September 30, 2017 2016 Expected volatility 54 % 49 % Risk-free interest rate 1.50 % 0.90 % Expected dividend — % — % Weighted average fair value $ 13.82 $ 4.94 The Company issued 43,200 performance-based restricted stock units in March 2014 with a grant date fair value of $12.30 per share. The vesting and issuance of Company stock pursuant to these awards depends on obtaining regulatory clearance of various products within a defined time. Stock-based compensation expense for performance-based awards is recognized when it is probable that the applicable performance criteria will be satisfied. The probability of achieving the relevant performance criteria is evaluated on a quarterly basis. As of September 30, 2017 , there was $133,000 of unrecognized stock-based compensation expense related to these awards. Employee Stock Purchase Plan The Company's stockholders approved the ESPP in May 2013. A total of 650,000 shares of the Company’s common stock were originally reserved for issuance under the ESPP, which permits eligible employees to purchase common stock at a discount through payroll deductions. The price at which stock is purchased under the ESPP is equal to 85% of the fair market value of the Company's common stock on the first or the last day of the offering period, whichever is lower. Generally, each offering under the ESPP will be for a period of six months as determined by the Company's Board of Directors; provided that no offering period may exceed 27 months. Employees may invest up to 10% of their qualifying gross compensation through payroll deductions. In no event may an employee purchase more than 1,500 shares of common stock during any six-month offering period. As of September 30, 2017 , there were 207,183 shares of common stock available for issuance under the ESPP. The ESPP is a compensatory plan as defined by the authoritative guidance for stock compensation; therefore, stock-based compensation expense related to the ESPP has been recorded during the nine months ended September 30, 2017 .

Net Loss per Common Share

Net Loss per Common Share	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Net Loss per Common Share	Net Loss per Common Share Basic net loss per share is calculated by dividing loss available to stockholders of the Company's common stock (the numerator) by the weighted average number of shares of the Company's common stock outstanding during the period (the denominator). Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted loss per share is calculated in a similar way to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the dilutive potential shares had been issued, unless the effect would be anti-dilutive. The computations of diluted net loss per share for the three and nine month periods ended September 30, 2017 and 2016 did not include the effects of the following stock options and other equity awards which were outstanding as of the end of each period because the inclusion of these securities would have been anti-dilutive (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Options outstanding to purchase common stock 2,526 2,611 2,526 2,611 Other unvested equity awards 2,466 2,057 2,466 2,057 Total 4,992 4,668 4,992 4,668

Inventories

Inventories	9 Months Ended
	Sep. 30, 2017
Inventory Disclosure [Abstract]
Inventories	Inventories Inventory on hand as of September 30, 2017 and December 31, 2016 comprised the following (in thousands): September 30, 2017 December 31, 2016 Raw materials $ 2,795 $ 2,171 Work-in-process 2,709 1,488 Finished goods 1,605 2,974 Total inventories $ 7,109 $ 6,633

Property and Equipment, net

Property and Equipment, net	9 Months Ended
	Sep. 30, 2017
Property, Plant and Equipment, Net [Abstract]
Property and Equipment, net	Property and Equipment, net Property and equipment as of September 30, 2017 and December 31, 2016 comprised the following (in thousands): September 30, 2017 December 31, 2016 Property and equipment — at cost: Machinery and laboratory equipment $ 12,607 $ 10,145 Instruments 13,203 9,869 Office equipment 1,970 1,714 Leasehold improvements 10,497 10,100 Total property and equipment — at cost 38,277 31,828 Less: accumulated depreciation (16,691 ) (13,560 ) Property and equipment, net $ 21,586 $ 18,268 Depreciation expense was $1,206,000 and $854,000 for the three months ended September 30, 2017 and 2016 , respectively, and was $3,413,000 and $2,458,000 for the nine months ended September 30, 2017 and 2016 , respectively.

Intangible Assets, net

Intangible Assets, net	9 Months Ended
	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, net	Intangible Assets, net Intangible assets as of September 30, 2017 and December 31, 2016 comprised the following (in thousands): September 30, 2017 December 31, 2016 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Licensed intellectual property $ 4,750 $ (1,978 ) $ 2,772 $ 4,250 $ (1,580 ) $ 2,670 In July 2012, the Company entered into a development collaboration and license agreement with Advanced Liquid Logic, Inc., or ALL, which was acquired by Illumina, Inc. in July 2013. Under the terms of the agreement, the Company established a collaborative program to develop in-vitro diagnostic products incorporating ALL’s proprietary electro-wetting technology in conjunction with the Company’s electrochemical detection technology. During the nine months ended September 30, 2017 , the Company satisfied certain commercial milestones under this agreement requiring the payment of $ 500,000 , which was recorded as licensed intellectual property. Intellectual property licenses had a weighted average remaining amortization period of 4.68 years as of September 30, 2017 . Amortization expense for these licenses was $151,000 and $94,000 for the three months ended September 30, 2017 and 2016 , respectively, and was $398,000 and $281,000 for the nine months ended September 30, 2017 and 2016 , respectively. Estimated future amortization expense for these licenses is as follows (in thousands): Fiscal Years Ending Future Amortization Expense Remaining in 2017 $ 148 2018 593 2019 593 2020 593 2021 593 Thereafter 252 Total $ 2,772

Loan Payable

Loan Payable	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Long-term Debt [Text Block]	Loan Payable As of September 30, 2017 and December 31, 2016 , long-term debt comprised the following (in thousands): September 30, 2017 December 31, 2016 Term Loans Term Loan A - 6.9% principal $ 10,000 $ 10,000 Term Loan B - 6.9% principal 10,000 10,000 Term Loan C - 7.4% principal 15,000 — Final fee obligation 1,537 400 Repayment of principal (6,060 ) — Unamortized issuance costs (1,011 ) (585 ) Total debt, net 29,466 19,815 Current portion of long-term debt (19,548 ) (7,935 ) Long-term debt $ 9,918 $ 11,880 Term Loans In January 2015, the Company entered into a Loan and Security Agreement, or the LSA, with Solar Capital Partners (as successor-in-interest to General Electric Capital Corporation), and certain other financial institutions party thereto, as lenders, pursuant to which the Company obtained up to $35,000,000 in a series of term loans and a revolving loan in the maximum amount of $5,000,000 . As of June 2017, the Company had borrowed all $35,000,000 under the term loans as provided in the LSA. The term loans accrue interest at a rate equal to, ( a) the greater of 1.00% or the 3-year treasury rate in effect at the time of funding, plus (b) an applicable margin between 4.95% and 5.90% per annum. The Company was only required to make interest payments on amounts borrowed pursuant to the Term Loans from the applicable funding date until June 15, 2017 , or the Interest Only Period. Following the Interest Only Period, monthly installments of principal and interest under the Term Loans will be due until the original principal amount and applicable interest is fully repaid by January 12, 2019 , or the Maturity Date. Under the LSA, the Company is required to comply with certain affirmative and negative covenants, including, without limitation, delivering reports and notices relating to the Company’s financial condition and certain regulatory events and intellectual property matters, as well as limiting the creation of liens, the incurrence of indebtedness, and the making of certain investments, dividends, payments and acquisitions, other than as specifically permitted by the LSA. As of September 30, 2017 , the Company was in compliance with all covenants under the LSA. Revolving Loan Pursuant to the LSA, the Company may borrow up to $5,000,000 under a revolving loan facility. Borrowings under the revolving loan would accrue interest at a rate equal to (a) the greater of 1.25% per annum or a base rate as determined by a three-month LIBOR-based formula, plus (b) an applicable margin between 2.95% and 3.95% based on certain criteria as set forth in the LSA. All principal and interest outstanding under the revolving loan is due and payable on the Maturity Date. The Company is required to pay a commitment fee equal to 0.75% per annum of the amounts made available but unborrowed under the revolving loan. As of September 30, 2017 , the Company had not borrowed any of the $5,000,000 available under the revolving loan. Debt Issuance Costs As of September 30, 2017 and December 31, 2016 , the Company had $1,011,000 and $585,000 , respectively, of unamortized debt issuance discount, which is offset against borrowings in long-term and short-term debt. Amortization of debt issuance costs was $398,000 and $108,000 , for the three months ended September 30, 2017 and 2016 , respectively, and was $891,000 and $277,000 for the nine months ended September 30, 2017 and 2016 , respectively. Amortization of debt issuance costs is included as interest expense in the Company's unaudited condensed consolidated statements of comprehensive loss for the periods presented. Letter of Credit In September 2012, the Company provided a $758,000 letter of credit issued by Banc of California to the landlord of its executive office facility in Carlsbad, California. This letter of credit was secured with $758,000 of restricted cash as of September 30, 2017 .

Leases

Leases	9 Months Ended
	Sep. 30, 2017
Leases [Abstract]
Leases	Leases The Company has operating and capital lease agreements for its office, manufacturing, warehousing and laboratory space and for office equipment. Rent and operating expenses charged under these arrangements was $399,000 and $476,000 for the three months ended September 30, 2017 and 2016 , respectively, and was $1,211,000 and $1,460,000 for the nine months ended September 30, 2017 and 2016 , respectively. Pursuant to the Company's lease agreements, a portion of the monthly rent has been deferred. The balance of deferred rent as of September 30, 2017 and December 31, 2016 was $3,781,000 and $4,097,000 , respectively. As of September 30, 2017 , the future minimum lease payments required over the next five years under the Company's lease arrangements are as follows (in thousands): Fiscal Years Ending Future Minimum Lease Payments Remaining in 2017 $ 447 2018 1,868 2019 1,989 2020 1,997 2021 1,372 Thereafter 1,366 Total $ 9,039

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying amounts of financial instruments, such as cash equivalents, restricted cash, accounts receivable, and accounts payable approximate the related fair values due to the short-term maturities of these instruments. The Company uses a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value: • Level 1 — Quoted prices in active markets for identical assets or liabilities. • Level 2 — Inputs, other than Level 1, that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The following table presents the financial instruments measured at fair value on a recurring basis and the valuation approach applied to each class of financial instruments as of September 30, 2017 and December 31, 2016 (in thousands): September 30, 2017 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Cash equivalents Money market funds $ 9,129 $ — $ — $ 9,129 Corporate notes and bonds — 4,000 — 4,000 Marketable securities Corporate notes and bonds — 41,787 — 41,787 U.S. government and agency securities — 13,984 — 13,984 Commercial paper — 3,985 — 3,985 Total $ 9,129 $ 63,756 $ — $ 72,885 December 31, 2016 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Cash equivalents Money market funds $ 556 $ — $ — $ 556 Marketable securities Corporate notes and bonds — 18,821 — 18,821 U.S. government and agency securities — 3,503 — 3,503 Commercial paper — 3,283 — 3,283 Total $ 556 $ 25,607 $ — $ 26,163 Level 2 marketable securities are priced using quoted market prices for similar instruments or nonbinding market prices that are corroborated by observable market data. The Company uses inputs such as actual trade data, benchmark yields, broker/dealer quotes, and other similar data, which are obtained from quoted market prices, independent pricing vendors, or other sources, to determine the ultimate fair value of these assets and liabilities. The Company uses such pricing data as the primary input to make its assessments and determinations as to the ultimate valuation of its investment portfolio and has not made, during the periods presented, any material adjustments to such inputs.

Marketable Securities (Notes)

Marketable Securities (Notes)	9 Months Ended
	Sep. 30, 2017
Marketable Securities [Abstract]
Marketable Securities	Marketable Securities The following table summarizes the Company’s marketable securities as of September 30, 2017 and December 31, 2016 (in thousands): September 30, 2017 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Corporate notes and bonds $ 41,793 $ 1 $ (7 ) $ 41,788 U.S. government and agency securities 13,982 2 — 13,984 Commercial paper 3,985 — — 3,985 Total $ 59,760 $ 3 $ (7 ) $ 59,756 December 31, 2016 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Corporate notes and bonds $ 18,846 $ — $ (25 ) $ 18,821 U.S. government and agency securities 3,506 — (3 ) 3,503 Commercial paper 3,283 — — 3,283 Total $ 25,635 $ — $ (28 ) $ 25,607 The following table summarizes the maturities of the Company’s marketable securities as of September 30, 2017 (in thousands): Amortized Cost Estimated Fair Value Due in one year or less $ 59,760 $ 59,756 Due after one year through two years — — Total $ 59,760 $ 59,756

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter. As of September 30, 2017 , the Company recorded a full valuation allowance against all of its net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the future. Due to the Company's losses, it only records a tax provision or benefit related to uncertain tax positions and related interest and minimum tax payments or refunds. The Company recorded an income tax benefit of $9,000 for the three months ended September 30, 2017 and income tax expense of $14,000 for the three months ended September 30, 2016 , and income tax expense of $68,000 and $45,000 for the nine months ended September 30, 2017 and 2016 , respectively. The Company is subject to taxation in the United States and in various state and foreign jurisdictions. The Company's federal and state returns since inception are subject to examination due to the carryover of net operating losses. As of September 30, 2017 , the Company’s tax years from 2011 through 2012 are subject to examination by the United Kingdom tax authorities related to its legacy operations. The statute of limitations for the assessment and collection of income taxes related to other foreign tax returns varies by country. In the foreign countries where the Company has operations, these time periods generally range from three to five years after the year for which the tax return is due or the tax is assessed.

Organization and Basis of Pre17

Organization and Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP, and applicable regulations of the U.S. Securities and Exchange Commission, or the SEC, and should be read in conjunction with the audited financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2016 filed with the SEC on February 28, 2017. These unaudited condensed consolidated financial statements reflect all adjustments that are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. These adjustments are of a normal, recurring nature. Interim period operating results may not be indicative of the operating results for the full year or any future period. The Company has experienced net losses and negative cash flows from operating activities since its inception and had an accumulated deficit of $402,584,000 as of September 30, 2017 . The Company's ability to transition to profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure through expanding its product offerings and consequently increasing its product revenues. As of September 30, 2017 , the Company had available cash, cash equivalents, and marketable securities of $86,917,000 and working capital of $68,857,000 available to fund future operations. The Company has prepared cash flow forecasts which indicate, based on the Company's current cash resources available and working capital, that the Company will have sufficient resources to fund its operations for at least one year after the date the financial statements are issued.
Priniciples of Consolidation	Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Segment Information	Segment Information The Company currently operates in one reportable business segment, which encompasses the development, manufacturing, sales and support of instruments and molecular tests based on its proprietary eSensor® detection technology. Substantially all of the Company’s operations and assets are in the United States of America.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that the Company adopts as of the specified effective date. In November 2016, the FASB issued Accounting Standards Update, or ASU, 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash , which requires amounts generally described as restricted cash and restricted cash equivalents to be included in the cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-08 is effective for fiscal years beginning after December 15, 2017 (including interim periods within those periods) using a retrospective transition method for each period presented. Early adoption is permitted. The Company will adopt ASU 2016-18 in the first quarter of 2018 and anticipates the impact of adoption will result in a beginning and ending cash balance increase of approximately $758,000 . The Company does not anticipate a material impact in the cash flow resulting from fluctuations in the restricted cash balance. In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting . This guidance simplifies how several aspects of share-based payments are accounted for and presented in the financial statements and is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company's adoption of this guidance in the first quarter of 2017 resulted in excess tax benefits for which a benefit could not be previously recognized of approximately $1,979,000 . Upon adoption, the balance of the unrecognized excess tax benefits was reversed with the impact recorded to retained earnings, including a corresponding change to the valuation allowance. Due to the full valuation allowance on the Company's U.S. deferred tax assets, there was no impact to the unaudited condensed consolidated financial statements as a result of adoption. The Company continues to record stock-based compensation expense net of estimated forfeitures. In February 2016, the FASB issued ASU 2016-02, Leases . This ASU outlines a comprehensive lease accounting model and supersedes the current lease guidance. The new guidance requires lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms of greater than 12 months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. The new guidance must be adopted using the modified retrospective approach and will be effective for the Company starting in the first quarter of 2019, with early adoption permitted. The Company believes that adoption will modify its analysis and disclosures of lease agreements as operating agreements are a significant portion of the Company's total lease commitments. The Company is in the process of determining the effects adoption of this guidance will have on its consolidated financial statements, as well as whether to adopt this guidance early. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, an updated standard on revenue recognition. ASU 2014-09 provides enhancements to the quality and consistency of how revenue is reported by companies while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards or U.S. GAAP. The main purpose of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which a company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures of revenue, provide guidance for transactions that were not previously addressed comprehensively, and improves guidance for multiple-element arrangements. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date , which deferred the effective date of the new revenue standard from periods beginning after December 15, 2016 to December l5, 2017, with early adoption permitted but not earlier than the original effective date. Accordingly, the updated standard is effective for the Company in the first quarter of 2018. The Company performed a preliminary assessment of the impact of ASU 2014-09 on its consolidated financial statements, and considered all items outlined in the standard. In assessing the impact, the Company has outlined all revenue generating activities, mapped those activities to deliverables and traced those deliverables to the standard. The Company is now assessing what impact the change in standard will have on those deliverables. The Company will continue to evaluate the future impact and method of adoption of ASU 2014-09 and related amendments on its consolidated financial statements and related disclosures during the remainder of 2017. The Company believes the adoption of this guidance will modify the manner in which the Company analyzes its revenue generating contracts. The Company will adopt the new standard beginning January 2018.
Cash, Cash Equivalents and Marketable Securities	Cash, Cash Equivalents and Marketable Securities Cash and cash equivalents consist of cash on deposit with banks, money market instruments and certificates of deposit with original maturities of three months or less at the date of purchase. Marketable securities consist of certificates of deposits that mature in greater than three months. Marketable securities are accounted for as "available-for-sale" with the carrying amounts reported in the balance sheets stated at cost, which approximates their fair market value, with unrealized gains and losses, if any, reported as a separate component of stockholders' equity and included in comprehensive loss.
Receivables	Receivables Accounts receivable consist of amounts due to the Company for sales to customers and are recorded net of an allowance for doubtful accounts. The allowance for doubtful accounts is determined based on an assessment of the collectability of specific customer accounts, the aging of accounts receivable, and a reserve for unknown items based upon the Company’s historical experience.
Restricted Cash	Restricted Cash Restricted cash represents amounts designated for uses other than current operations and included $758,000 as of September 30, 2017 , held as security for the Company’s letter of credit with Banc of California.
Use of Estimates	Use of Estimates The preparation of these unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes thereto. The Company’s significant estimates included in the preparation of the financial statements are related to accounts receivable, inventories, property and equipment, intangible assets, employee-related compensation accruals, warranty liabilities, tax valuation accounts and stock-based compensation. Actual results could differ from those estimates.
Product Warranties	Product Warranties The Company generally offers a one -year warranty for its instruments sold to customers and typically up to a 60 day warranty for consumables. Factors that affect the Company’s warranty reserves include the number of units sold, historical and anticipated rates of warranty repairs, and the cost per repair. The Company periodically assesses the adequacy of its warranty reserve and adjusts the amount as appropriate.
Intangible Assets	Intangible Assets Intangible assets comprise licenses or sublicenses to technology covered by patents owned by third parties, and are amortized on a straight-line basis over the expected useful lives of these assets, which is generally 10 years . Amortization of licenses typically begins upon the Company obtaining access to the licensed technology and is recorded in cost of revenues for licenses supporting commercialized products. The amortization of licenses to technology supporting products in development is recorded in research and development expenses.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company assesses the recoverability of long-lived assets, including intangible assets, by periodically evaluating the carrying value whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If impairment is indicated, the Company writes down the carrying value of the asset to its estimated fair value. This fair value is primarily determined based on estimated discounted future cash flows.
Inventories	Inventories Inventories are stated at the lower of cost (first-in, first-out) or net realizable value and include direct labor, materials, and manufacturing overhead. The Company periodically reviews inventory for evidence of slow-moving or obsolete parts, and writes inventory down to net realizable value, as needed. This write-down is based on management’s review of inventories on hand, compared to estimated future usage and sales, shelf-life assumptions, and assumptions about the likelihood of obsolescence. If actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Inventory impairment charges establish a new cost basis for inventory and charges are not reversed subsequently to income, even if circumstances later suggest that increased carrying amounts are recoverable.
Property, Plant and Equipment, net	Property and Equipment, net Property, equipment and leasehold improvements are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which are identified below. Repair and maintenance costs are expensed as incurred. Machinery and laboratory equipment 3 - 5 years Instruments 4 - 5 years Office equipment 3 - 7 years Leasehold improvements over the shorter of the remaining life of the lease or the useful economic life of the asset
Income Taxes	Income Taxes Current income tax expense is the amount of income taxes expected to be payable for the current year. A deferred income tax liability or asset is established for the expected future tax consequences resulting from the differences in financial reporting and tax bases of assets and liabilities. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. A full valuation allowance has been recorded against the Company’s net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the future. The Company provides for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement standards prescribed by the authoritative guidance on income taxes. Amounts for uncertain tax positions are adjusted in periods when new information becomes available or when positions are effectively settled. The Company recognizes accrued interest related to uncertain tax positions as a component of income tax expense. A tax position that is more likely than not to be realized is measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement with the taxing authority that has full knowledge of all relevant information. Measurement of a tax position that meets the more-likely-than-not threshold considers the amounts and probabilities of the outcomes that could be realized upon settlement using the facts, circumstances and information available at the reporting date.

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2017
Compensation Related Costs [Abstract]
Schedule of stock option activity	The following table summarizes stock option activity during the nine months ended September 30, 2017 : Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2016 2,569,550 $ 9.53 Granted — $ — Exercised (28,966 ) $ 7.36 Cancelled (14,427 ) $ 10.04 Outstanding at September 30, 2017 2,526,157 $ 9.56 Vested and expected to vest at September 30, 2017 2,500,450 $ 9.52 Exercisable at September 30, 2017 2,167,970 $ 9.18
Summary of restricted stock award and restricted stock units activity	The Company’s restricted stock award and restricted stock unit activity for the nine months ended September 30, 2017 was as follows: Restricted Stock Awards Restricted Stock Units Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Unvested at December 31, 2016 156 $ 11.19 1,766,123 $ 7.18 Granted — $ — 1,164,250 $ 10.90 Vested (156 ) $ 11.19 (614,457 ) $ 6.80 Cancelled — $ — (165,501 ) $ 8.99 Unvested at September 30, 2017 — $ — 2,150,415 $ 9.16
Schedule of Market-Based Stock Units Activity	The Company’s market-based stock unit activity for the nine months ended September 30, 2017 was as follows: Market-Based Stock Units Number of Shares Weighted Average Grant Date Fair Value Unvested at December 31, 2016 150,871 $ 11.10 Units granted 166,434 $ 13.82 Vested — $ — Cancelled (12,762 ) $ 11.90 Unvested at September 30, 2017 304,543 $ 12.55
Market-Based Stock Units Valuation Assumptions	The fair value of these market-based stock units was estimated on the grant date using the Monte Carlo Simulation Valuation Model, which estimates the potential outcome of achieving the market condition based on simulated future stock prices, with the following assumptions for the nine months ended September 30, 2017 : Nine Months Ended September 30, 2017 2016 Expected volatility 54 % 49 % Risk-free interest rate 1.50 % 0.90 % Expected dividend — % — % Weighted average fair value $ 13.82 $ 4.94

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share	The computations of diluted net loss per share for the three and nine month periods ended September 30, 2017 and 2016 did not include the effects of the following stock options and other equity awards which were outstanding as of the end of each period because the inclusion of these securities would have been anti-dilutive (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Options outstanding to purchase common stock 2,526 2,611 2,526 2,611 Other unvested equity awards 2,466 2,057 2,466 2,057 Total 4,992 4,668 4,992 4,668

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2017
Inventory Disclosure [Abstract]
Summary of inventory on hand	Inventory on hand as of September 30, 2017 and December 31, 2016 comprised the following (in thousands): September 30, 2017 December 31, 2016 Raw materials $ 2,795 $ 2,171 Work-in-process 2,709 1,488 Finished goods 1,605 2,974 Total inventories $ 7,109 $ 6,633

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	9 Months Ended
	Sep. 30, 2017
Property, Plant and Equipment, Net [Abstract]
Property and equipment, net	Property and equipment as of September 30, 2017 and December 31, 2016 comprised the following (in thousands): September 30, 2017 December 31, 2016 Property and equipment — at cost: Machinery and laboratory equipment $ 12,607 $ 10,145 Instruments 13,203 9,869 Office equipment 1,970 1,714 Leasehold improvements 10,497 10,100 Total property and equipment — at cost 38,277 31,828 Less: accumulated depreciation (16,691 ) (13,560 ) Property and equipment, net $ 21,586 $ 18,268

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	9 Months Ended
	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of intangible assets	Intangible assets as of September 30, 2017 and December 31, 2016 comprised the following (in thousands): September 30, 2017 December 31, 2016 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Licensed intellectual property $ 4,750 $ (1,978 ) $ 2,772 $ 4,250 $ (1,580 ) $ 2,670
Summary of estimated future amortization expense	Estimated future amortization expense for these licenses is as follows (in thousands): Fiscal Years Ending Future Amortization Expense Remaining in 2017 $ 148 2018 593 2019 593 2020 593 2021 593 Thereafter 252 Total $ 2,772

Loan Payable Tables (Tables)

Loan Payable Tables (Tables)	9 Months Ended
	Sep. 30, 2017
Debt Instrument [Line Items]
Schedule of Long-term Debt Instruments [Table Text Block]	As of September 30, 2017 and December 31, 2016 , long-term debt comprised the following (in thousands): September 30, 2017 December 31, 2016 Term Loans Term Loan A - 6.9% principal $ 10,000 $ 10,000 Term Loan B - 6.9% principal 10,000 10,000 Term Loan C - 7.4% principal 15,000 — Final fee obligation 1,537 400 Repayment of principal (6,060 ) — Unamortized issuance costs (1,011 ) (585 ) Total debt, net 29,466 19,815 Current portion of long-term debt (19,548 ) (7,935 ) Long-term debt $ 9,918 $ 11,880

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2017
Leases [Abstract]
Schedule of future minimum lease payments	As of September 30, 2017 , the future minimum lease payments required over the next five years under the Company's lease arrangements are as follows (in thousands): Fiscal Years Ending Future Minimum Lease Payments Remaining in 2017 $ 447 2018 1,868 2019 1,989 2020 1,997 2021 1,372 Thereafter 1,366 Total $ 9,039

Fair Value of Financial Instr25

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	The following table presents the financial instruments measured at fair value on a recurring basis and the valuation approach applied to each class of financial instruments as of September 30, 2017 and December 31, 2016 (in thousands): September 30, 2017 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Cash equivalents Money market funds $ 9,129 $ — $ — $ 9,129 Corporate notes and bonds — 4,000 — 4,000 Marketable securities Corporate notes and bonds — 41,787 — 41,787 U.S. government and agency securities — 13,984 — 13,984 Commercial paper — 3,985 — 3,985 Total $ 9,129 $ 63,756 $ — $ 72,885 December 31, 2016 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Cash equivalents Money market funds $ 556 $ — $ — $ 556 Marketable securities Corporate notes and bonds — 18,821 — 18,821 U.S. government and agency securities — 3,503 — 3,503 Commercial paper — 3,283 — 3,283 Total $ 556 $ 25,607 $ — $ 26,163

Marketable Securities (Tables)

Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2017
Marketable Securities [Abstract]
Available-for-sale Securities	The following table summarizes the Company’s marketable securities as of September 30, 2017 and December 31, 2016 (in thousands): September 30, 2017 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Corporate notes and bonds $ 41,793 $ 1 $ (7 ) $ 41,788 U.S. government and agency securities 13,982 2 — 13,984 Commercial paper 3,985 — — 3,985 Total $ 59,760 $ 3 $ (7 ) $ 59,756 December 31, 2016 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Corporate notes and bonds $ 18,846 $ — $ (25 ) $ 18,821 U.S. government and agency securities 3,506 — (3 ) 3,503 Commercial paper 3,283 — — 3,283 Total $ 25,635 $ — $ (28 ) $ 25,607
Investments Classified by Contractual Maturity Date	The following table summarizes the maturities of the Company’s marketable securities as of September 30, 2017 (in thousands): Amortized Cost Estimated Fair Value Due in one year or less $ 59,760 $ 59,756 Due after one year through two years — — Total $ 59,760 $ 59,756

Organization and Basis of Pre27

Organization and Basis of Presentation (Details)	9 Months Ended
	Sep. 30, 2017
Machinery and laboratory equipment | Minimum
Property, Plant and Equipment [Line Items]
Expected useful lives	3 years
Machinery and laboratory equipment | Maximum
Property, Plant and Equipment [Line Items]
Expected useful lives	5 years
Instruments | Minimum
Property, Plant and Equipment [Line Items]
Expected useful lives	4 years
Instruments | Maximum
Property, Plant and Equipment [Line Items]
Expected useful lives	5 years
Office equipment | Minimum
Property, Plant and Equipment [Line Items]
Expected useful lives	3 years
Office equipment | Maximum
Property, Plant and Equipment [Line Items]
Expected useful lives	7 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Expected useful lives	over the shorter of the remaining life of the lease or the useful economic life of the asset

Organization and Basis of Pre28

Organization and Basis of Presentation (Details Textual)	9 Months Ended
	Sep. 30, 2017USD ($)Segment	Dec. 31, 2016USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Restricted cash	$ 758,000	$ 758,000
Number of operating segment | Segment	1
Working Capital	$ 68,857,000
Accumulated deficit	402,584,000	$ 355,270,000
Cash, Cash Equivalents, and Short-term Investments	86,917,000
Excess tax benefit, amount	$ 1,979,000
Sufficient capital to fund its operations	for at least one year
Products Warranty Period - Reagents	60 days
Product Warranty Period - Instruments	1 year
Finite Lived Intangible Asset Amortization Period	10 years

Stock-Based Compensation Schedu

Stock-Based Compensation Schedule of Stock Options Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Mar. 31, 2016	Sep. 30, 2017
Compensation Related Costs [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term		5 years 1 month 11 days
Aggregate intrinsic value of options exercisable		$ 6,478
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value		$ 6,783
Weighted Average Remaining Contractual Life, Outstanding (in years)	6 years 8 months 27 days	5 years 5 months 2 days
Schedule of stock option activity
Number of Share options Outstanding, Beginning Balance		2,569,550
Number of Share options, Granted		0
Number of Share options, Exercised		(28,966)
Number of Share options, Cancelled		(14,427)
Number of Share options Outstanding, Ending Balance		2,526,157
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number		2,500,450
Number of Share options, Exercisable		2,167,970
Weighted average exercise price Outstanding, Beginning Balance		$ 9.53
Weighted average exercise price, Granted		0
Weighted average exercise price, Exercised		7.36
Weighted average exercise price, Cancelled		10.04
Weighted average exercise price Outstanding, Ending Balance		9.56
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price		9.52
Weighted average exercise price, Exercisable		$ 9.18

Stock-Based Compensation (Detai

Stock-Based Compensation (Details 2) - $ / shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Restricted Stock Awards [Member]
Summary of restricted stock award and restricted stock units activity
Non-vested, Number of shares, Beginning balance	156
Number of shares, Granted	0
Number of shares, Vested	(156)
Number of shares, Cancelled or expired	0
Non-vested, Number of shares, Ending balance	0
Non-vested, Weighted average Grant Date Fair Value, Beginning balance	$ 11.19
Weighted Average Grant Date Fair Value, Granted	0
Weighted average Grant Date Fair Value, Vested	11.19
Weighted average Grant Date Fair Value, Cancelled or expired	0
Non-vested, Weighted average Grant Date Fair Value, Ending balance	$ 0
Market Share Unit [Member]
Summary of restricted stock award and restricted stock units activity
Non-vested, Number of shares, Beginning balance	150,871
Number of shares, Granted	166,434
Number of shares, Cancelled or expired	(12,762)
Non-vested, Number of shares, Ending balance	304,543
Non-vested, Weighted average Grant Date Fair Value, Beginning balance	$ 11.10
Weighted Average Grant Date Fair Value, Granted	13.82	$ 4.94
Weighted average Grant Date Fair Value, Cancelled or expired	11.90
Non-vested, Weighted average Grant Date Fair Value, Ending balance	$ 12.55
Restricted Stock Units [Member]
Summary of restricted stock award and restricted stock units activity
Non-vested, Number of shares, Beginning balance	1,766,123
Number of shares, Granted	1,164,250
Number of shares, Vested	(614,457)
Number of shares, Cancelled or expired	(165,501)
Non-vested, Number of shares, Ending balance	2,150,415
Non-vested, Weighted average Grant Date Fair Value, Beginning balance	$ 7.18
Weighted Average Grant Date Fair Value, Granted	10.90
Weighted average Grant Date Fair Value, Vested	6.80
Weighted average Grant Date Fair Value, Cancelled or expired	8.99
Non-vested, Weighted average Grant Date Fair Value, Ending balance	$ 9.16

Stock-Based Compensation - Add

Stock-Based Compensation - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2014	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Sep. 30, 2013
Share-based compensation (Textual) [Abstract]
Granted Stock option			0
Stock compensation expense			$ 8,386,000	$ 6,788,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number			2,526,157		2,569,550
Weighted average exercise price of stock option			$ 0
Remaining weighted average contractual term			5 years 1 month 11 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value			$ 6,478,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value			6,783,000
Restricted Stock Awards [Member]
Share-based compensation (Textual) [Abstract]
Total fair value of restricted stock vested			2,000	152,000
Stock compensation expense			$ 8,386,000	$ 6,788,000
Number of shares, Granted			0
Weighted Average Grant Date Fair Value, Granted			$ 0
Market Share Unit [Member]
Share-based compensation (Textual) [Abstract]
Shares received as percent of target number of units granted	200.00%
Unrecognized compensation cost			$ 1,502,000
Weighted average-period, cost is expected to be recognized			1 year 7 months 3 days
Number of shares, Granted			166,434
Weighted Average Grant Date Fair Value, Granted			$ 13.82	$ 4.94
Expected volatility			54.00%	49.00%
Risk-free interest rate			1.50%	0.90%
Expected dividend			0.00%	0.00%
Restricted Stock Units [Member]
Share-based compensation (Textual) [Abstract]
Total fair value of restricted stock vested			$ 4,181,000	$ 4,526,000
Unrecognized compensation cost			$ 13,142,000
Weighted average-period, cost is expected to be recognized			2 years 9 months 4 days
Number of shares, Granted			1,164,250
Weighted Average Grant Date Fair Value, Granted			$ 10.90
Performance Shares [Member]
Share-based compensation (Textual) [Abstract]
Unrecognized compensation cost			$ 133,000
Number of shares, Granted		43,200
Weighted Average Grant Date Fair Value, Granted		$ 12.30
2010 Plan [Member] | Minimum
Share-based compensation (Textual) [Abstract]
Options vesting period			1 year
2010 Plan [Member] | Maximum
Share-based compensation (Textual) [Abstract]
Options vesting period			4 years
2010 Plan [Member] | Options [Member]
Share-based compensation (Textual) [Abstract]
Expiration period			10 years
2013 Employee Stock Purchase Plan [Member]
Employee Stock Purchase Plan [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						650,000
Common stock reserved for future issuance			207,183
Purchase price as a percent of the fair market value of the common stock			85.00%
Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period			6 months
Maximum offering period			27 months
Maximum employee investment in ESPP as a percentage of gross compensation			10.00%
Maximum shares of common stock that can be puchased by each employee			1,500

Net Loss per Common Share (Deta

Net Loss per Common Share (Details) - shares shares in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Computations of diluted net loss per share
Antidilutive securities excluded from calculation	4,992	4,668
Options [Member]
Computations of diluted net loss per share
Antidilutive securities excluded from calculation	2,526	2,611
Unvested restricted stock [Member]
Computations of diluted net loss per share
Antidilutive securities excluded from calculation	2,466	2,057

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Summary of inventory on hand
Raw materials	$ 2,795	$ 2,171
Work-in-process	2,709	1,488
Finished goods	1,605	2,974
Total	$ 7,109	$ 6,633

Property and Equipment, net (De

Property and Equipment, net (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Property and equipment-at cost:
Total property and equipment-at cost	$ 38,277		$ 38,277		$ 31,828
Less accumulated depreciation	(16,691)		(16,691)		(13,560)
Property and equipment, net	21,586		21,586		18,268
Depreciation expense	1,206	$ 854	3,413	$ 2,458
Machinery and laboratory equipment
Property and equipment-at cost:
Total property and equipment-at cost	12,607		12,607		10,145
Instruments
Property and equipment-at cost:
Total property and equipment-at cost	13,203		13,203		9,869
Office equipment
Property and equipment-at cost:
Total property and equipment-at cost	1,970		1,970		1,714
Leasehold improvements
Property and equipment-at cost:
Total property and equipment-at cost	$ 10,497		$ 10,497		$ 10,100

Intangible Assets, net - Gross

Intangible Assets, net - Gross and Net Carrying Values (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Finite-Lived Intangible Assets, Gross	$ 4,750	$ 4,250
Finite-Lived Intangible Assets, Accumulated Amortization	(1,978)	(1,580)
Finite-Lived Intangible Assets, Net	$ 2,772	$ 2,670

Intangible Assets, net - Future

Intangible Assets, net - Future Amortization Expense (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Remaining in 2017	$ 148
2,018	593
2,019	593
2,020	593
2,021	593
Thereafter	252
Finite-Lived Intangible Assets, Net	$ 2,772	$ 2,670

Intangible Assets, net - Additi

Intangible Assets, net - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Finite-lived Intangible Assets Acquired			$ 500,000
Amortization of Intangible Assets	$ 151,000	$ 94,000	$ 398,000	$ 281,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			4 years 8 months 6 days

Loan Payable Term Loans (Detail

Loan Payable Term Loans (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Loans Payable	$ 35,000,000	$ 20,000,000
Final fee obligation	1,537,000	400,000
Repayment of principal	(6,060,000)	0
Unamortized issuance costs	(1,011,000)	(585,000)
Total debt, net	29,466,000	19,815,000
Current portion of long-term debt	(19,548,000)	(7,935,000)
Long-term debt	9,918,000	11,880,000
Term Loan A - 6.9% principal
Debt Instrument [Line Items]
Loans Payable	$ 10,000,000	$ 10,000,000
Debt Instrument, Interest Rate, Stated Percentage	6.90%	6.90%
Term Loan B - 6.9% principal
Debt Instrument [Line Items]
Loans Payable	$ 10,000,000	$ 10,000,000
Debt Instrument, Interest Rate, Stated Percentage	6.90%	6.90%
Term Loan C - 7.4% principal
Debt Instrument [Line Items]
Loans Payable	$ 15,000,000	$ 0
Debt Instrument, Interest Rate, Stated Percentage	7.40%	0.00%
Term Loans [Member]
Debt Instrument [Line Items]
Loans Payable	$ 35,000,000
Debt Instrument, Interest Rate Terms	a) the greater of 1.00% or the 3-year treasury rate in effect at the time of funding, plus (b) an applicable margin between 4.95% and 5.90% per annum.
Debt Interest only Period End	Jun. 15, 2017
Debt Instrument, Maturity Date	Jan. 12, 2019

Loan Payable Revolving Credit F

Loan Payable Revolving Credit Facility (Details) - Revolving Credit Facility [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2017USD ($)
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 5,000
Line of Credit Facility, Interest Rate Description	the greater of 1.25% per annum or a base rate as determined by a three-month LIBOR-based formula, plus (b) an applicable margin between 2.95% and 3.95%
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.75%
Minimum
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate	2.95%
Maximum
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate	3.95%

Loan Payable - Additional Infor

Loan Payable - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Debt Disclosure [Abstract]
Unamortized issuance costs	$ (1,011,000)		$ (1,011,000)		$ (585,000)
Amortization of deferred debt issuance costs	398,000	$ 108,000	891,000	$ 277,000
Letters of Credit Outstanding, Amount	$ 758,000		$ 758,000

Leases (Details)

Leases (Details) $ in Thousands	Sep. 30, 2017USD ($)
Schedule of future minimum lease payments
Remaining in 2017	$ 447
2,015	1,868
2,016	1,989
2,017	1,997
2,018	1,372
Thereafter	1,366
Total future minimum payments	$ 9,039

Leases (Details Textual)

Leases (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Leases [Abstract]
Rent and operating expenses	$ 398,777	$ 476,000	$ 1,211,264	$ 1,460,000
Operating lease, deferred expense	$ 3,780,528		$ 3,780,528		$ 4,097,000

Fair Value of Financial Instr43

Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities, fair value	$ 59,756	$ 25,607
Total financial instruments at fair value	72,885	26,163
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	9,129	556
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities, fair value	63,756	25,607
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities, fair value	0	0
Money market funds | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	9,129	556
Money market funds | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Money market funds | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Corporate notes and bonds | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0
Marketable securities, fair value	0	0
Corporate notes and bonds | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	4,000
Marketable securities, fair value	41,787	18,821
Corporate notes and bonds | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0
Marketable securities, fair value	0	0
U.S. government and agency securities | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities, fair value	0	0
U.S. government and agency securities | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities, fair value	13,984	3,503
U.S. government and agency securities | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities, fair value	0	0
Commercial paper | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities, fair value	0	0
Commercial paper | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities, fair value	3,985	3,283
Commercial paper | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities, fair value	$ 0	$ 0

Marketable Securities - Gross u

Marketable Securities - Gross unrealized gains/losses on marketable securities (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 59,760	$ 25,635
Gross Unrealized Gains	3	0
Gross Unrealized Losses	(7)	(28)
Marketable securities, fair value	59,756	25,607
Corporate notes and bonds
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	41,793	18,846
Gross Unrealized Gains	1	0
Gross Unrealized Losses	(7)	(25)
Marketable securities, fair value	41,788	18,821
U.S. government and agency securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	13,982	3,506
Gross Unrealized Gains	2	0
Gross Unrealized Losses	0	(3)
Marketable securities, fair value	13,984	3,503
Commercial paper
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	3,985	3,283
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Marketable securities, fair value	$ 3,985	$ 3,283

Marketable Securities - Contrac

Marketable Securities - Contractual maturities of marketable securities (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 59,760	$ 25,635
Marketable securities, fair value	59,756	$ 25,607
Due in one year or less [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	59,760
Marketable securities, fair value	59,756
Due after one year through two years [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	0
Marketable securities, fair value	$ 0

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ (9,000)	$ 14,000	$ 68,000	$ 45,000